Various systemic therapies for psoriasis either reduced, slightly increased or had no effect on risk for major adverse ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Abdominal obesity is a greater risk factor for psoriasis than total body fat, according to an analysis of imaging data, ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

NutritionistLearn all about psoriasis, a chronic inflammatory disease, including common symptoms, treatments, plus which diet ...

In adults with psoriasis, adding methotrexate to adalimumab did not improve effectiveness or drug survival compared with ...

US claims data show patients with generalized pustular psoriasis (GPP) face up to a 4-fold higher mortality risk compared ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...